When the Treatment is the Cause: Disseminated Bacille Calmette–Guérin Infection

  • Ana Teresa Marques Afonso Internal Medicine Department, University Hospital of Santiago de Compostela, A Coruña, Spain
  • Montserrat Rodríguez Framil Internal Medicine Department, University Hospital of Santiago de Compostela, A Coruña, Spain
  • Joaquín Sánchez Leira Internal Medicine Department, University Hospital of Santiago de Compostela, A Coruña, Spain
  • Néstor Vázquez Agra Internal Medicine Department, University Hospital of Santiago de Compostela, A Coruña, Spain
  • Federico García-Rodeja Arias Cardiology Department, University Hospital of Santiago de Compostela, A Coruña, Spain

Keywords

BCG infection, miliary tuberculosis, hepatitis

Abstract

Bacille Calmette–Guérin (BCG) administration for superficial bladder cancer is a well-tolerated and very effective therapy. However, unpredictable systemic complications may occur on rare occasions. We present the case of a patient who attended for consultation because of fever, asthenia and weight loss following BCG immunotherapy. The clinical response to treatment and computed tomography scanning were key to diagnosis.

VIEW THE ENTIRE ARTICLE

References

  • Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179(1):53–56.

  • Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175(6):2004–2010.

  • Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido A, San Juan R, et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 2014;93(17):236–254.

  • Kaburaki K, Sugino K, Sekiya M, Takai Y, Shibuya K, Homma S. Miliary tuberculosis that developed after intravesical bacillus Calmette-Guerin therapy. Intern Med 2017;56(12):1563–1567.

  • Siatelis A, Houhoula DP, Papaparaskevas J, Delakas D, Tsakris A. Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma. J Clin Microbiol 2011;49(4):1206–1208.

  • Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147(3):596–600.
  • Published: 2020-06-03

    Issue: Vol 7 No 9 (view)

    Section: Articles

    How to cite:
    1.
    Afonso ATM, Framil MR, Leira JS, Agra NV, Arias FG-R. When the Treatment is the Cause: Disseminated Bacille Calmette–Guérin Infection. EJCRIM [Internet]. 2020Jun.3 [cited 2020Sep.24];7(9). Available from: https://ejcrim.com/index.php/EJCRIM/article/view/1697